Latest News
- Psoriasis
Tuesday, December 11, 2018
Dermatologists Need More Info About Cannabinoids
Dermatologists are interested in learning more about cannabinoids and recommending them to patients, according to a new survey in Journal of Drugs in Dermatology. However, many are concerned a…
Read the full storyTuesday, December 04, 2018
New PsA Guidelines from National Psoriasis and Rheumatology Orgs Recommend Treat-to-Target Approach
Newly released psoriatic Arthritis (PsA) treatment guidelines from the National Psoriasis Foundation (NPF) and the American College of Rheumatology (ACR) are calling for a treat-to-target approac…
Read the full storyWednesday, November 28, 2018
Study: Lipid that Aids Normal Skin Turnover May Help Psoriasis
A lipid that helps keep skin cell turnover on track may help restore healthy turnover in psoriasis, investigators say. Topical application of the lipid phosphatidylglycerol, or PG, on a mouse model of…
Read the full storyWednesday, November 28, 2018
Encore Dermatology Announces Phase 2 Safety Data for Impoyz
A Phase 2, open-label study published in SKIN The Journal of Cutaneous Medicine, found that subjects treated with Impoyz (clobetasol propionate) Cream, 0.025% showed significantly lower mean post-trea…
Read the full storyWednesday, November 07, 2018
Ortho Dermatologics Gears Up to Launch Bryhali Lotion for Plaque Psoriasis
Ortho Dermatologics expects to start distribution of Bryhali (halobetsasol propionate) Lotion, 0.01%, to U.S. wholesale pharmaceutical distributors later this month. The company received final appr…
Read the full storyWednesday, October 24, 2018
IBD Linked to Psoriasis in Large Meta-Analysis
A new meta-analysis comprising more than 7 million people suggests it may be time to add inflammatory bowel disease (IBD) to the list of comorbidities associated with psoriasis. The findi…
Read the full story
Tuesday, October 23, 2018
Ilumya Now Available for Moderate-to-Severe Plaque Psoriasis
Ilumya™ (tildrakizumab-asmn) 100mg/mL from Sun Pharmaceutical Industries Ltd. is now available in the United States. Ilumya is an injectable interleukin-23 (IL-23) inhibitor approved by the FDA …
Read the full storyThursday, October 18, 2018
Amgevita, Amgen's Biosimilar Adalimumab, Launches in Europe
Amgen's Amgevita, a biosimilar to adalimumab, has launched in markets across Europe. Amgevita is the first adalimumab biosimilar to be approved by the European Commission …
Read the full storyWednesday, October 17, 2018
Psoriasis Plus Hypertension Equals Greater Need for Heart Surgery
Patients with psoriasis and hypertension need more cardiovascular procedures and surgeries than hypertensive patients without psoriasis, a new study in the Journal of Dermatology suggests. In 5.62 …
Read the full story
Tuesday, October 09, 2018
Online Care May Be As Effective as In-Person Care for Psoriasis
Teledermatology may be as effective as seeing a doctor in person when it comes to improving the symptoms of psoriasis, according to a new study in JAMA Network Open. “Patients with chronic sk…
Read the full storyMonday, October 08, 2018
Ortho Dermatologics Receives Tentative FDA Approval for Bryhali for Plaque Psoriasis
The FDA has provided tentative approval of the New Drug Application for Bryhali (halobetasol propionate) Lotion, 0.01%, for the topical treatment of plaque psoriasis in adult patients. Bryhali Lotion …
Read the full story
Friday, October 05, 2018
EPI Acquires Rights to Cloderm Cream from Promius Pharma
EPI Health has acquired the rights rights to Cloderm® (clocortolone pivalate) Cream, 0.1% and its authorized generic from Promius Pharma, LLC, a wholly owned subsidiary of D…
Read the full storyTuesday, October 02, 2018
Ortho Dermatologics’ Bryhali Lotions Performs Well in Two Phase 3 Psoriasis Trials
Two Phase 3 randomized controlled trials show that Bryhali (halobetasol propionate) Lotion, 0.01%, an investigational potent to superpotent corticosteroid in the treatment of moderate-to-severe p…
Read the full story
Monday, September 17, 2018
UCB: Study Data for Cimzia and Bimekizumab Presented at EADV
UCB has presented new findings on Cimzia® (certolizumab pegol) and one of its key pipeline molecules, bimekizumab, for the treatment of moderate-to-severe chronic plaque psoriasis (PSO), along wit…
Read the full story
Monday, September 17, 2018
Almirall and Evotec Form Dermatology Research Collaboration
Alrimal and Evotec aim to discover and develop first-in-class therapeutics through a novel approach to disrupt cell signaling, that is expected to deliver highly potent and durable treatments for debi…
Read the full story
